Scarica l'app Stockscreener
5.5432
4.03%
-0.0832
Artiva Biotherapeutics Inc Borsa (ARTV) Ultime notizie
BZ2704 Forecast — Price Prediction for 2026. Should I Buy BZ2704? - Intellectia AI
Artiva Biotherapeutics (ARTV) Expected to Announce Earnings on Monday - MarketBeat
ARTV SEC FilingsARTIVA BIOTHERAPEUTICS INC 10-K, 10-Q, 8-K Forms - Stock Titan
If You Invested $1,000 in ARTIVA BIOTHERAPEUTICS INC (ARTV) - Stock Titan
FFAIW Should I Buy - Intellectia AI
POWWP Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
LEGT Should I Buy - Intellectia AI
Market Rankings: Can PROP deliver consistent EPS growth2026 Analyst Calls & Risk Controlled Swing Alerts - baoquankhu1.vn
Should I add Artiva Biotherapeutics Inc stock to my portfolio2026 Big Picture & Community Verified Trade Signals - baoquankhu1.vn
02652 Should I Buy - Intellectia AI
TOLL Should I Buy - Intellectia AI
GRABW Should I Buy - Intellectia AI
Wedbush Maintains Artiva Biotherapeutics (ARTV) Outperform Recommendation - MSN
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Sees Significant Decrease in Short Interest - MarketBeat
Artiva Biotherapeutics, Inc. (ARTV) Receives a Buy from Jefferies - The Globe and Mail
Research Analysts Issue Forecasts for ARTV Q1 Earnings - MarketBeat
Analysts Offer Insights on Healthcare Companies: Artiva Biotherapeutics, Inc. (ARTV) and Edgewise Therapeutics (EWTX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Artiva Biotherapeutics, Inc. (ARTV) and Clinigence Holdings (NUTX) - The Globe and Mail
Artiva Biotherapeutics (NASDAQ:ARTV) Given Buy Rating at Needham & Company LLC - Defense World
Artiva Biotherapeutics, Inc. 2025 Annual Report: Business Overview, Risk Factors, and Strategic Outlook - Minichart
Artiva Biotherapeutics' (ARTV) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
Artiva: Sufficient Cash Runway to 2027 Supports Buy Rating Ahead of Key 2026 RA Efficacy Readouts - TipRanks
ARTV: AlloNK shows promise in refractory RA as clinical and financial milestones approach in 2026 - TradingView
Artiva Biotherapeutics 10-K: Revenue $0.0M, Net Loss $(83.9)M — Cash $108.0M - TradingView
ARTV: 2025 net loss widened to $83.9M as R&D spending increased; cash runway extends into Q2 2027 - TradingView
Artiva Biotherapeutics posts 2025 results, prepares for RA clinical data in early 2026 - Traders Union
Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights - marketscreener.com
Growth Value: Is Stantec Inc on track to beat earningsWeekly Volume Report & Expert Curated Trade Ideas - baoquankhu1.vn
What insider trading reveals about Artiva Biotherapeutics Inc. stock2026 Price Swings & Advanced Swing Trade Entry Plans - Naître et grandir
Dow Update: Does Artiva Biotherapeutics Inc have consistent dividend growthWeekly Gains Summary & Technical Buy Zone Confirmation - baoquankhu1.vn
Artiva Biotherapeutics Pivots to Rheumatoid Arthritis at TD Cowen, Teases 2026 RA Data Update - MarketBeat
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference - GlobeNewswire
Artiva Biotherapeutics appoints Thad Huston as chief financial officer - Investing.com Australia
Artiva Biotherapeutics appoints Thad Huston as chief financial officer By Investing.com - Investing.com South Africa
Artiva Biotherapeutics Appoints Thad Huston as Chief Financial Officer - TipRanks
Artiva Biotherapeutics, Inc. Appoints Thad Huston as Principal Financial Officer and Principal Accounting Officer, Effective from February 18, 2026 - marketscreener.com
Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant - The Globe and Mail
Artiva Biotherapeutics Announces Appointment Of Thad Huston As CFO - TradingView
Artiva Biotherapeutics Announces Appointment of Thad Huston - GlobeNewswire
Is Artiva Biotherapeutics Inc. on track to beat earningsJuly 2025 Retail & Daily Profit Maximizing Tips - mfd.ru
Artiva Biotherapeutics Inc. (ARTV) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Can Artiva Biotherapeutics Inc. keep up with sector leaders2025 Institutional Moves & AI Driven Stock Movement Reports - mfd.ru
Will Artiva Biotherapeutics Inc. benefit from rate cutsJuly 2025 Weekly Recap & Consistent Profit Alerts - mfd.ru
Artiva Biotherapeutics appoints pharma veteran Elaine Sorg to board By Investing.com - Investing.com India
Earnings Miss: Does Artiva Biotherapeutics Inc. have consistent dividend growthWeekly Stock Report & Precise Trade Entry Recommendations - mfd.ru
Artiva Biotherapeutics Adds Veteran Executive Elaine Sorg to Board - The Globe and Mail
Artiva Biotherapeutics appoints pharma veteran Elaine Sorg to board - Investing.com Australia
Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors - Bitget
AtaiBeckley Appoints Michael Faerm as Chief Financial Officer - The Manila Times
Sell Signal: Is LINKBANCORP Inc a defensive stockJuly 2025 PreEarnings & High Yield Equity Trading Tips - baoquankhu1.vn
Aug Momentum: Does Artiva Biotherapeutics Inc have consistent dividend growth2025 Key Lessons & Precise Buy Zone Tips - baoquankhu1.vn
Will Artiva Biotherapeutics Inc. stock benefit from sector rotation2025 Dividend Review & Real-Time Buy Signal Notifications - mfd.ru
Can Artiva Biotherapeutics Inc. stock continue upward trendWeekly Loss Report & Free High Accuracy Swing Entry Alerts - mfd.ru
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Short Interest Down 28.5% in January - MarketBeat
Artiva Biotherapeutics, Inc. (RTVA.US) Latest News & Headlines - Longbridge
Is Artiva Biotherapeutics Inc. stock risky to hold nowJuly 2025 Momentum & Long-Term Growth Portfolio Plans - mfd.ru
Published on: 2026-02-12 04:11:50 - mfd.ru
0.99%
3.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):